http://www.afxpress.com/afxpress2/html/story_1954557.xml
Last update 14:40:06 GMT
FRANKFURT (AFX) - Shares in Schering
AG were lower midafternoon amid expectations that its multiple sclerosis
treatment Betaferon Rebif will be overshadowed by rival products from Serono
SA and Biogen Inc, dealers said.
At 3.16 pm, Schering shares were
down 1.45 eur or 2.26 pct at 62.85. The DAX 30 was at 5,922.19, down 4.19
points or 0.07 pct.
The three drugs are currently pitted
against each other in a head-to-head clinical trial in the U.S.
scs/jkm/
June 22